First Time in Human Study (FTIH) With Positron Emission Tomography (PET)

Exclusion Criteria

• •The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
• •A positive pre-study hepatitis B surface antigen (HBsAg) or positive hepatitis C virus (HCV) antibody test result within 3 months of Screening.
• •A positive test result for antibodies to human immunodeficiency virus (HIV)-1/2.
• •Significant renal abnormality (from medical history or as indicated by laboratory investigations. In addition, subjects with idiopathic haematuria or proteinuria or conditions such as benign orthostatic proteinuria and benign familial haematuria should be excluded from the study).
• •History of regular alcohol consumption within 6 months of the study start defined as:
• •• An average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males), or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a half-pint (220 mL) of beer or 1 measure (25 mL) of spirits or 1 glass (125 mL) of wine.
• •The subject has participated in a clinical trial and has received an investigational product within 3 month prior to the first investigational product dosing day in the current study.
• •Exposure to more than four new chemical entities within 12 months prior to the first investigational product dosing day.
• •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to receiving the first dose of the investigational product, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
• •History of sensitivity to any of the investigational products, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates their participation in the study.
• •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56-day period.
• •Unwillingness or inability to follow the procedures outlined in the protocol.
• •History or presence of clinically significant cardiac arrhythmias, or other clinically significant cardiac disease.
• •Smokers confirmed by a positive urinary cotinine test (greater than the local laboratory lower limit of quantification \[LLQ\] of 200 ng/mL or lower). Urine cotinine levels will be measured during Screening and at Baseline.
• •Consumption of Seville oranges (including marmalade) and/or grapefruit and/or Chinese grapefruit (pomelo) and/or grapefruit hybrids and/or exotic citrus fruits and/or their fruit juices from 7 days prior to the first investigational product dosing day.
• •Consumption of red wine from 7 days prior to the first investigational product dosing day